Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
Edgewise Therapeutics reported a Q1 2026 net loss of $49.0 million, or $0.46 per share, with cash, cash equivalents and marketable securities totaling approximately $499.6 million as of March 31, 2026. The company announced positive long-term data from the MESA open-label extension trial, demonstrating that sevasemten sustained functional stabilization in patients with Becker muscular dystrophy for up to 3.5 years.
Key figures
- Net loss
- $49.0 million
- Ga expenses
- $11.5 million
- Rd expenses
- $42.7 million
- Cash position
- $499.6 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.